4.7 Review

Antibiotic strategies in the era of multidrug resistance

Journal

CRITICAL CARE
Volume 20, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/s13054-016-1320-7

Keywords

-

Funding

  1. Bayer
  2. Pfizer
  3. Basilea
  4. Astellas
  5. Cubist-Merck
  6. Kenta-Aridis
  7. Medimmune-AstraZeneca
  8. Abbott Laboratories
  9. Actelion
  10. Astra-Zeneca
  11. Cerexa
  12. Cubist
  13. Durata
  14. European Tissue Symposium
  15. Medicines Company
  16. MedImmune
  17. Merck
  18. Motif Biosciences
  19. Nabriva
  20. Optimer
  21. Paratek
  22. Roche
  23. Sanofi-Pasteur
  24. Seres
  25. Summit
  26. Synthetic Biologics
  27. Abbott
  28. Alere
  29. bioMerieux
  30. Da Volterra

Ask authors/readers for more resources

The rapid emergence and dissemination of antibiotic-resistant microorganisms in ICUs worldwide threaten adequate antibiotic coverage of infected patients in this environment. The causes of this problem are multifactorial, but the core issues are clear: the emergence of antibiotic resistance is highly correlated with selective pressure resulting from inappropriate use of these drugs. Because a significant increase in mortality is observed when antibiotic therapy is delayed in infected ICU patients, initial therapy should be broad enough to cover all likely pathogens. Receipt of unnecessary prolonged broad-spectrum antibiotics, however, should be avoided. Local microbiologic data are extremely important to predict the type of resistance that may be present for specific causative bacteria, as is prior antibiotic exposure, and antibiotic choices should thus be made at an individual patient level.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available